{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T04:05:53Z","timestamp":1748837153242,"version":"3.41.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This article aims at describing the role of neoadjuvant chemotherapy, radiation therapy as well the novel immunotherapy and targeted therapy in thoracic oncology with focus on anesthetic considerations of such treatments for the surgical patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In recent years, immune check point inhibitors have changed the landscape of thoracic oncology treatment. In this review, we summarize the key studies that have been fundamental in this change.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Rather than a comprehensive review, the purpose of this work is to provide the reader with an overview of the most common neoadjuvant regimens used in current practice, with the corresponding most prevalent adverse effects as it pertains for patients with esophageal and lung cancer, malignant pleural mesothelioma and mediastinal tumors. Considerations relevant to the anesthesiologist, including specific toxicities related to each treatment type, and the impact of each treatment type on perioperative outcomes and complications will be discussed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aco.0000000000001224","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T05:00:08Z","timestamp":1671771608000},"page":"74-82","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Presurgical radiation and chemotherapy in preparation for thoracic tumor resection"],"prefix":"10.1097","volume":"36","author":[{"given":"Iran","family":"Tavakoli","sequence":"first","affiliation":[{"name":"Division of Thoracic Surgery, University of Toronto, Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon R.","family":"Turner","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilitch","family":"Diaz-Gutierrez","sequence":"additional","affiliation":[{"name":"Assistant Professor, Division of Thoracic and Foregut Surgery, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"R3-20250601","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41416-021-01485-9","article-title":"Advances in the curative management of oesophageal cancer","volume":"126","author":"Bolger","year":"2022","journal-title":"Br J Cancer"},{"key":"R4-20250601","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"R6-20250601","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"R8-20250601","doi-asserted-by":"crossref","first-page":"100934","DOI":"10.1016\/j.conctc.2022.100934","article-title":"chemotherapy and chemoradiotherapy for adenocarcinoma of the oesophagus and esophagogastric junction with oligometastases: protocol of the TNT-OES-1 trial","volume":"28","author":"van der Zijden","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"R9-20250601","article-title":"Adjuvant nivolumab in esophageal or gastroesophageal junction cancer: the improvement in progression-free survival is small","author":"Mengato","year":"2022","journal-title":"J Gastrointest Cancer"},{"key":"R10-20250601","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"R11-20250601","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/fon-2018-0581","article-title":"KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer","volume":"15","author":"Bang","year":"2019","journal-title":"Future Oncol"},{"key":"R14-20250601","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0169-5002(99)00045-8","article-title":"Preresectional chemotherapy in stage IIIA nonsmall-cell lung cancer: a 7-year assessment of a randomized controlled trial","volume":"26","author":"Rosell","year":"1999","journal-title":"Lung Cancer"},{"key":"R15-20250601","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jnci\/86.9.673","article-title":"A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage iiia nonsmall-cell lung cancer","volume":"86","author":"Roth","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R16-20250601","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 nonsmall-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"R17-20250601","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"(Suppl 1)","key":"R18-20250601","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"key":"R19-20250601","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R20-20250601","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"R21-20250601","article-title":"Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA\/IIIB nonsmall cell lung cancer: a single-arm, phase 2 trial","author":"Sun","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"R22-20250601","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","article-title":"Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial","volume":"22","author":"Cho","year":"2021","journal-title":"Lancet Oncol"},{"key":"R23-20250601","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod Pathol"},{"key":"R25-20250601","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"R26-20250601","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"R27-20250601","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12885-022-09490-8","article-title":"Systemic treatment in patients with malignant pleural mesothelioma \u2013 real life experience","volume":"22","author":"Zi\u00f3\u0142kowska","year":"2022","journal-title":"BMC Cancer"},{"key":"R30-20250601","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.athoracsur.2006.11.077","article-title":"Stereotactic radiosurgery for the treatment of lung neoplasm: initial experience","volume":"83","author":"Pennathur","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R31-20250601","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB nonsmall-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"R32-20250601","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"R33-20250601","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2217\/fon-2021-0021","article-title":"Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis","volume":"17","author":"Han","year":"2021","journal-title":"Futur Oncol"},{"key":"R34-20250601","doi-asserted-by":"crossref","first-page":"836.e1","DOI":"10.1016\/j.jtcvs.2020.11.106","article-title":"Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer","volume":"161","author":"Sihag","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R35-20250601","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.athoracsur.2017.09.030","article-title":"Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer","volume":"105","author":"Yang","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"R36-20250601","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1053\/j.semtcvs.2021.07.014","article-title":"Nononcologic mortality after pneumonectomy compared to lobectomy","volume":"34","author":"Yun","year":"2022","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"R37-20250601","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Nonsmall cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R38-20250601","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40140-015-0121-x","article-title":"Perioperative implications of neoadjuvant therapies and optimization strategies for cancer surgery","volume":"5","author":"Sahai","year":"2015","journal-title":"Curr Anesthesiol Rep"},{"key":"R40-20250601","doi-asserted-by":"crossref","first-page":"593","DOI":"10.21037\/tlcr.2018.05.07","article-title":"A randomized phase II study of pleurectomy\/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205)","volume":"7","author":"Raskin","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R41-20250601","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.athoracsur.2018.08.055","article-title":"Comparison of neoadjuvant chemotherapy followed by surgery to upfront surgery for thymic malignancy","volume":"107","author":"Park","year":"2019","journal-title":"Ann Thorac Surg"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T22:03:09Z","timestamp":1748815389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000001224","relation":{},"ISSN":["0952-7907","1473-6500"],"issn-type":[{"type":"print","value":"0952-7907"},{"type":"electronic","value":"1473-6500"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}